Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs OPCH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OPCH Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

OPCH Overall Winner 6-Pillar Tally: AHCO 3 – 3 OPCH Matrix Metrics: AHCO 3 – 7 OPCH

As of Nov 20, 2026, Option Care Health, Inc. (OPCH) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas OPCH carries 53.9/100 (HOLD) at $31.59 (15.2x Forward P/E, 5.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs OPCH
AHCO NASDAQ
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
OPCH NASDAQ Head-to-Head Winner
Option Care Health, Inc. Common Stock
Services-Home Health Care Services
$31.59
-0.06% 1D
Market Cap $4.7B
TTM Revenue $5.75B
Forward P/E 15.2x
Beta / 30D Vol -0.04β · 7% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 45.0 Fund 47.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.3% over 20 days), RSI 69
RSI-14: 69.0 · SMA20: $31.62 · SMA50: $28.87

6-Pillar Scorecard Institutional Category Breakdown (AHCO 3 – 3 OPCH)

Columns: Metric · AHCO · OPCH
1. Valuation Multiples AHCO
Forward P/E 7.8x 15.2x
Trailing P/E 7.8x 22.9x
PEG Ratio N/M 1.50x
EV / Revenue 0.9x 0.8x
2. Growth & Scale OPCH
Revenue Growth (YoY) +10.9% +4.1%
Earnings Growth (YoY) +6.7% +18.8%
TTM Revenue (USD) $3.44B $5.75B
Market Cap $989.8M $4.7B
3. Profitability & Quality OPCH
Gross Margin 18.2% 19.1%
Operating Margin 3.8% 5.9%
Net Profit Margin -11.8% 3.7%
Return on Equity (ROE) -28.4% 16.0%
4. Balance Sheet & Cash Flow OPCH
Cash Generation (TTM) $82M $412M EBITDA
Cash Flow Margin 2.4% 7.2% EBITDA Mgn
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $8.84 Book/Sh · 16.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 66.9% (12th %ile) 39.0% (76th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat AHCO
OpEx & R&D Intensity 14.4% of Rev ($495M) 13.2% of Rev ($759M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (3) vs OPCH (7)
Institutional Metric AHCO OPCH Criterion Row Edge
Market Capitalization
Scale
$989.8M $4.7B Larger Scale OPCH
Trailing P/E Ratio
Valuation
7.8x 22.9x Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x 15.2x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +4.1% Higher Growth AHCO
Operating Margin (TTM)
Profitability
3.8% 5.9% Higher Margin OPCH
Net Profit Margin
Profitability
-11.8% 3.7% Higher Margin OPCH
Return on Equity (ROE)
Capital Efficiency
-28.4% 16.0% Higher ROE OPCH
52-Week Range Position
Momentum
24% ($5–$13) 72% ($18–$37) Stronger Trend OPCH
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol -0.04β · 7% Vol Lower Realized Risk OPCH
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 53.9 / 100 (HOLD) Higher Composite OPCH
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $5.75B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 19.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 1.50x PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) $412M EBITDA ($8.84 Book/Sh · 16.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +15.73 pp
AHCO: +16.69% · OPCH: +0.96%
3M Horizon OPCH +5.57 pp
AHCO: +27.89% · OPCH: +33.46%
6M Horizon OPCH +82.03 pp
AHCO: -31.1% · OPCH: +50.93%
1Y Horizon OPCH +34.64 pp
AHCO: -20.88% · OPCH: +13.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AHCO vs OPCH. Trailing 12-month operating profitability (AHCO 3.8% vs OPCH 5.9%) and valuation multiples (AHCO 7.8x vs OPCH 15.2x Forward P/E) are benchmarked directly in Pillar 4 below.

AHCO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.44B
Gross Margin18.2%
Op. Margin3.8%
ROE / Fwd P/E-28.4% · 7.8x
OPCH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.75B
Gross Margin19.1%
Op. Margin5.9%
ROE / Fwd P/E16.0% · 15.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OPCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 39.0%
IV Percentile 76th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OPCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
OPCH Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $4.7B market capitalization and 5.9% operating margin.
OpEx & R&D Reinvestment 13.2% of Rev ($759M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs OPCH Key Questions & Quantitative Answers

As of Nov 20, 2026, Option Care Health, Inc. (OPCH) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas OPCH carries 53.9/100 (HOLD) at $31.59 (15.2x Forward P/E, 5.9% operating margin). Technically, AHCO sits in a Markup phase (RSI 57.1, SURGE options structure) and OPCH sits in a Markup phase (RSI 69.0, UNCLASSIFIED options structure).

OPCH leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with OPCH at +4.1% YoY revenue growth and +18.8% YoY earnings growth on $5.75B TTM revenue (19.1% gross margin, 5.9% operating margin). On trailing 12-month operating scale, AHCO generates $3.44B in USD-normalized revenue versus $5.75B for OPCH. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 13.2% of Rev ($759M) (0 disclosures) for OPCH.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas OPCH trades at 15.2x Forward P/E, 22.9x Trailing P/E, 1.50x PEG, and 0.8x EV/Revenue (7.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus OPCH (16.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, OPCH carries 39.0% implied volatility (76th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.04β · 7% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.